Inactive Instrument

Pacific Software Inc Share Price Other OTC

Equities

US69482P1066

Personal Products

End-of-day quote Other OTC
- USD - Intraday chart for Pacific Software Inc
Sales 2019 - Sales 2020 0.02 1.57 Capitalization 48.35M 3.79B
Net income 2019 -21M -1.65B Net income 2020 -1M -78.49M EV / Sales 2019 -
Net cash position 2019 101K 7.89M Net Debt 2020 367K 28.84M EV / Sales 2020 2,435,972,350 x
P/E ratio 2019
-2.65 x
P/E ratio 2020
-41.2 x
Employees -
Yield 2019 *
-
Yield 2020
-
Free-Float 1.49%
More Fundamentals * Assessed data
Pacific Software, Inc. acquired Certain assets of Dreamaderm Inc. from Dreamaderm Inc. CI
Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020 CI
Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019 CI
Pacific Software, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020 CI
Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2018 CI
Pacific Software Inc. Enters into Memorandum of Understanding with Império Assessoria em Informaçoes LTDA CI
Pacific Software, Inc. completed the spin-off of Hypersoft Ventures. CI
Pacific Software Inc. Partners with Prominent Brazilian Trade Association to Market Its E-Commerce Trade Portal BOAPIN.com CI
Pacific Software, Inc. Issues Update on Launch of E-Commerce Trade Platform CI
Pacific Software, Inc. agreed to spin-off Hypersoft Ventures. CI
Pacific Software, Inc. Begins Development of its Blockchain Technology Based B2B/B2C E-Commerce Platform CI
Pacific Software Inc. Collaborates with KB Quest Group Inc. to Design IBM-Based Hyperledger Blockchain Technology Solutions Commercially CI
Pacific Software Inc. Announces Engagement of Wang-Chan Wong Ph.D. to Serve on Independent Advisory Board CI
Pacific Software, Inc. Appoints Peter Pizzino as President and Director CI
John Simmonds Resigns as Director of Pacific Software CI
More news
Pacific Software, Inc. is a technology company that specializes in the development and commercialization of advanced skincare solutions. The Company’s cosmeceutical asset is branded as Dermatrix. Dermatrix prevents the breakdown of insulin by blocking the action of insulin-degrading enzyme (IDE), a peptidase that is abundant within the skin. Insulin directly stimulates collagen production, thus Dermatrix has the effect of maximizing the body's own natural collagen-producing processes. By blocking IDE, Dermatrix also maintains the levels of other peptides vital to skin health and repair processes, such as keratinocyte growth and migration. Dermatrix is used for a considerable variety of products in both the skin care and wound healing sectors. The Company is also focused on science-based dietary supplement supporting brain health and memory function.
More about the company